NASDAQ:CAI Caris Life Sciences (CAI) Stock Price, News & Analysis $25.44 +0.37 (+1.47%) As of 12:40 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Caris Life Sciences Stock (NASDAQ:CAI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Caris Life Sciences alerts:Sign Up Key Stats Today's Range$24.88▼$25.5950-Day Range$15.38▼$28.0152-Week Range$14.19▼$35.20Volume1.92 million shsAverage Volume3.20 million shsMarket Capitalization$7.19 billionP/E Ratio70.56Dividend YieldN/APrice Target$26.33Consensus RatingModerate Buy Company Overview Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology. Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis. In addition to clinical testing for patient care, the company offers translational science and clinical trial support services to biopharmaceutical partners, including biomarker discovery, assay development and companion diagnostic collaborations to facilitate drug development programs. The company primarily serves healthcare providers, cancer centers and biopharma customers in the United States and through international collaborations. Its offerings are used across the oncology care continuum—from initial profiling to inform therapy selection through longitudinal monitoring and research applications—positioning the business at the intersection of clinical diagnostics and precision oncology research. Caris emphasizes the integration of multi‑omic data and computational analysis to generate clinically actionable insights, and it engages with clinicians, researchers and industry partners to expand the use of molecular profiling in personalized cancer care. Detailed information about its leadership and corporate history is available through the company’s public filings and corporate disclosures. AI Generated. May Contain Errors. Read More Caris Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreCAI MarketRank™: Caris Life Sciences scored higher than 45% of companies evaluated by MarketBeat, and ranked 536th out of 906 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.2 / 5Analyst RatingModerate Buy Consensus RatingCaris Life Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 7 buy ratings, 4 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Caris Life Sciences is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageCaris Life Sciences has only been the subject of 3 research reports in the past 90 days.Read more about Caris Life Sciences' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth200.00% Earnings GrowthEarnings for Caris Life Sciences are expected to grow by 200.00% in the coming year, from $0.13 to $0.39 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Caris Life Sciences is 70.57, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.24.Price to Earnings Ratio vs. SectorThe P/E ratio of Caris Life Sciences is 70.57, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.80.Price to Book Value per Share RatioCaris Life Sciences has a P/B Ratio of 12.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.58% of the float of Caris Life Sciences has been sold short.Short Interest Ratio / Days to CoverCaris Life Sciences has a short interest ratio ("days to cover") of 2.54, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Caris Life Sciences has recently increased by 1.34%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCaris Life Sciences does not currently pay a dividend.Dividend GrowthCaris Life Sciences does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.63 News SentimentCaris Life Sciences has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Caris Life Sciences this week, compared to 4 articles on an average week.Search InterestOnly 5 people have searched for CAI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Caris Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,834,769.00 in company stock.Percentage Held by Insiders50.00% of the stock of Caris Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsCaris Life Sciences has minimal institutional ownership at this time.Read more about Caris Life Sciences' insider trading history. Receive CAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Caris Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CAI Stock News HeadlinesCaris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris DetectSeptember 8 at 6:30 AM | prnewswire.comCaris Life Sciences (CAI) & The Competition Head-To-Head ContrastSeptember 8 at 4:29 AM | americanbankingnews.comDOJ Just Said Your Cash Isn’t “Property”The Department of Justice recently argued in court that cash isn't legally property, raising fresh questions about ownership of everyday savings. The implications stretch beyond legal theory, touching bank accounts, retirement funds, and decades of accumulated wealth. A free information kit outlines three strategies Americans are considering to help protect their savings from future policy shifts.September 8 at 1:00 AM | Priority Gold (Ad)Insider Selling: Caris Life Sciences (NASDAQ:CAI) President Sells $11,883,080.00 in StockSeptember 7 at 4:08 AM | americanbankingnews.comCould Caris Life Sciences (CAI) Be 7% Undervalued After Its Lung Cancer Research Update?September 6 at 9:17 AM | finance.yahoo.comCaris Life Sciences (CAI) Will Present Seven Studies At A Global Lung ConferenceSeptember 5 at 5:18 PM | finance.yahoo.comInsider Selling: Caris Life Sciences (NASDAQ:CAI) President Sells 119,212 SharesSeptember 5 at 6:52 AM | insidertrades.comCaris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung CancerSeptember 2, 2026 | prnewswire.comSee More Headlines CAI Stock Analysis - Frequently Asked Questions How have CAI shares performed this year? Caris Life Sciences' stock was trading at $26.98 at the beginning of the year. Since then, CAI shares have decreased by 6.0% and is now trading at $25.3480. How were Caris Life Sciences' earnings last quarter? Caris Life Sciences, Inc. (NASDAQ:CAI) issued its earnings results on Thursday, February, 26th. The company reported $0.28 EPS for the quarter, topping analysts' consensus estimates of $0.01 by $0.27. Caris Life Sciences's revenue for the quarter was up 125.4% compared to the same quarter last year. Read the conference call transcript. Is Caris Life Sciences doing a stock buyback? Caris Life Sciences' board authorized a stock repurchase plan on Monday, June 8th 2026, which authorizes the company to repurchase $100,000,000 in shares, according to EventVestor. This means that the company could reacquire up to 2.2% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's leadership believes its shares are undervalued. When did Caris Life Sciences IPO? Caris Life Sciences (CAI) raised $459 million in an IPO on Wednesday, June 18th 2025. The company issued 23,529,412 shares at a price of $19.00-$20.00 per share. Who are Caris Life Sciences' major shareholders? Top institutional shareholders of Caris Life Sciences include Braidwell LP (2.92%), PointState Capital LP (2.42%), BlackRock Inc. (1.96%) and California State Teachers Retirement System (1.15%). Insiders that own company stock include David Baxley Spetzler, Jon Halbert, Luke Thomas Power and Jeff L Vacirca. View institutional ownership trends. How do I buy shares of Caris Life Sciences? Shares of CAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings2/26/2026Today9/08/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 4 weeks, CAI's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:CAI CIK2019410 Webwww.carislifesciences.com Phone(866) 771-8946FaxN/AEmployees1,846Year Founded2008Price Target and Rating Average Price Target for Caris Life Sciences$26.33 High Price Target$33.00 Low Price Target$21.00 Potential Upside/Downside+3.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)$0.36 Trailing P/E Ratio70.56 Forward P/E Ratio195.68 P/E GrowthN/ANet Income-$68.09 million Net Margins10.62% Pretax Margin10.61% Return on Equity18.77% Return on Assets9.34% Debt Debt-to-Equity Ratio0.66 Current Ratio5.53 Quick Ratio4.88 Sales & Book Value Annual Sales$812.03 million Price / Sales8.85 Cash Flow$1.62 per share Price / Cash Flow15.73 Book Value$2.05 per share Price / Book12.41Miscellaneous Outstanding Shares282,600,000Free Float141,298,000Market Cap$7.19 billion OptionableN/A Beta1.10 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:CAI) was last updated on 9/8/2026 by MarketBeat.com Staff. From Our Partners2:59 PM Friday. I make this trade.Tim Sykes says he books gains almost every weekend using one simple move. The trade is placed around 2:59 p...Tim Sykes | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredGold Explorer Sits Between Barrick’s Nevada GiantsBarrick Mining has spent decades building one of Nevada's richest gold districts, anchored by Fourmile, Goldru...Wall Street Logic | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredThe 2026 beginners Guide to Gold IRAsGold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...Goldco Direct, LLC | SponsoredAmerican retirees will miss THIS. Big Banks just moved in.Central banks spent nearly $130 billion on physical gold last year, on top of $145 billion the year before. Q1...Cedar Gold Group | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altuche...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Caris Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Caris Life Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
